Launch excellence, in medical affairs, is the planning and work a medical team does in the years before a product is approved so that the evidence, the external experts, and the field team are ready on the day it launches. It answers three questions before approval: which evidence gaps clinicians, guideline committees, and payers will raise, which experts the organization still does not know, and what the field team has to learn before it can hold a scientific conversation about the new data. Those decisions are recorded in an integrated evidence plan.
Quick answer: The Medical Affairs Professional Society (MAPS) publishes the reference standard for medical launch excellence. Its public summary describes a 48-month timeline that starts about four years before approval, and four pillars that Medical Affairs leads: stakeholder engagement, scientific education, evidence generation including real-world evidence, and organizational readiness. MAPS measures success by updated clinical guidelines, access, and better patient care pathways, not by commercial targets alone.
Commercial teams have used "launch excellence" for years to describe how well a brand launch performs against its forecast. The medical sense is narrower and starts earlier. It asks whether the science around a new product will be understood, questioned, and discussed accurately once the label is public, and whether medical affairs has done the work that makes that possible.
MAPS set out that view in its Launch Excellence standards and guidance, published in June 2025. The full document is available to MAPS members. The public summary is enough to show the shape of it: a long runway, a medical function that leads rather than supports, and measures of success that sit outside the sales forecast. Teams that want the full framework should read it at the source.
A Phase 3 program is designed to win approval. It is rarely designed to answer every question a treating physician, a guideline panel, or a payer will ask in the first year. Typical gaps are the patient who was excluded from the trial, the comparison with the current standard of care that was never run head to head, the long-term outcome, and the subgroup where the effect looks different. A launch plan lists those gaps early and decides which ones to close with further studies, real-world evidence, or investigator-initiated research, and which ones the team will have to discuss honestly as open.
The trial investigators are usually well known to the company by Phase 3. The clinicians who will shape practice after launch often are not. They include community specialists, guideline authors outside the trial network, and younger experts whose influence is growing. Building that map, and deciding where each expert sits through KOL tiering, takes time, which is why launch plans start it years ahead.
MSLs need to know the disease, the data, the competing science, and the boundaries of what they can discuss before approval. They also need a route for what they hear. A question an expert asks about the trial design, or a concern about a safety signal, is a medical insight that should reach the people writing the plan. Scientific education runs in both directions: the field learns the data, and the organization learns from the field.
MAPS places the start of launch preparation about four years before approval and stresses that the first six months set the direction for the rest. In practice the plan moves from evidence strategy, to expert mapping, to hiring and training the field team, to the readiness checks in the months before the decision. The detailed sequence for the field team during Phase 3, including when to map before hiring, is covered in pre-launch field medical.
Once those MSLs are hired, they need a place to keep the expert plan and the record of each visit. TikaMSL is where they work: the KOL plan, the scientific visit and its outcome, and the inquiry captured on that visit sit on one record in a medical affairs CRM that runs beside the CRM the company already uses.
MAPS points to medical outcomes: whether clinical guidelines are updated, whether appropriate patients get access, and whether care pathways change. Those take time to show up, so teams also track early signs during the launch window. Examples include how many of the mapped experts have had a scientific conversation about the new data, how quickly unsolicited questions are answered, and how many field insights changed the evidence plan. Each team sets its own targets. The point is to agree before launch on what medical success looks like, so it is not judged only by sales.
In medical affairs, launch excellence is the planning and work done in the years before approval so that evidence, external experts, and the field team are ready at launch. MAPS publishes a reference standard for it built on four pillars: stakeholder engagement, scientific education, evidence generation, and organizational readiness.
The MAPS Launch Excellence guidance describes a 48-month timeline that begins about four years before approval, with the first six months setting the direction for the rest of the plan.
Commercial launch excellence is usually judged against the sales forecast. Medical launch excellence asks whether the science will be understood and discussed accurately after approval, and MAPS measures it by updated guidelines, access, and changes in patient care pathways.
It means the medical team, its processes, and its systems are in place before approval: MSLs hired and trained, medical information ready to answer questions about the new label, an insights process that reaches the people writing the plan, and the records to show what was done.
If your team is planning a first launch and wants to see how the expert plan and the field record sit together, we can walk through it with your own therapeutic area.
Book a 20-minute walkthrough →